<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-27 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-27</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-27</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-dc59cf0817a22dbcb93b5dca7d880320ac39d4b2</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/dc59cf0817a22dbcb93b5dca7d880320ac39d4b2" target="_blank">The transcriptional landscape and mutational profile of lung adenocarcinoma</a></p>
                <p><strong>Paper Venue:</strong> Genome Research</p>
                <p><strong>Paper TL;DR:</strong> The first large scale RNA sequencing study of lung adenocarcinoma is presented, demonstrating its power to identify somatic point mutations as well as transcriptional variants such as gene fusions, alternative splicing events, and expression outliers.</p>
                <p><strong>Paper Abstract:</strong> All cancers harbor molecular alterations in their genomes. The transcriptional consequences of these somatic mutations have not yet been comprehensively explored in lung cancer. Here we present the first large scale RNA sequencing study of lung adenocarcinoma, demonstrating its power to identify somatic point mutations as well as transcriptional variants such as gene fusions, alternative splicing events, and expression outliers. Our results reveal the genetic basis of 200 lung adenocarcinomas in Koreans including deep characterization of 87 surgical specimens by transcriptome sequencing. We identified driver somatic mutations in cancer genes including EGFR, KRAS, NRAS, BRAF, PIK3CA, MET, and CTNNB1. Candidates for novel driver mutations were also identified in genes newly implicated in lung adenocarcinoma such as LMTK2, ARID1A, NOTCH2, and SMARCA4. We found 45 fusion genes, eight of which were chimeric tyrosine kinases involving ALK, RET, ROS1, FGFR2, AXL, and PDGFRA. Among 17 recurrent alternative splicing events, we identified exon 14 skipping in the proto-oncogene MET as highly likely to be a cancer driver. The number of somatic mutations and expression outliers varied markedly between individual cancers and was strongly correlated with smoking history of patients. We identified genomic blocks within which gene expression levels were consistently increased or decreased that could be explained by copy number alterations in samples. We also found an association between lymph node metastasis and somatic mutations in TP53. These findings broaden our understanding of lung adenocarcinoma and may also lead to new diagnostic and therapeutic approaches.</p>
                <p><strong>Cost:</strong> 0.026</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e27.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e27.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Receptor tyrosine kinase frequently activated by point mutations in lung adenocarcinoma (exon 19 deletions, L858R, G719A) and a major actionable driver in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 19 deletions; L858R; G719A</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>60.5% (121/200 overall cohort); 22/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq and targeted Sanger screening); recurrence across samples</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known activating mutations with established oncogenic function (drug-responsive in prior clinical studies cited in paper); no new functional assays in this study</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>High prevalence in this Korean cohort; referred to as target of EGFR TKIs (e.g., gefitinib) in Discussion</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Established target of EGFR inhibitors (e.g., gefitinib); clinical relevance noted</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>200 (87 analyzed by RNA-seq)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sanger screening (exons 18-21) and RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e27.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Kirsten rat sarcoma viral oncogene homolog</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>GTPase commonly activated by hotspot codon 12/13 substitutions in lung adenocarcinoma (multiple G12/G13 alleles observed).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS G12C, G12V, G12D, G12S, G13C, G13D</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>12.0% (24/200 overall cohort); 18/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq and screening) and recurrence</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known activating hotspot mutations established in prior work; no new functional assays in this study</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutually exclusive with most other canonical drivers in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Implications discussed as canonical driver; no novel therapeutics evaluated in this study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>200 (87 RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sanger sequencing (KRAS exon 2) and RNA-seq</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e27.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroblastoma RAS viral oncogene homolog</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>RAS family member with activating codon 61 substitutions detected in a small number of lung adenocarcinomas in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NRAS Q61H, Q61L, Q61K</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NRAS / RAS-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3/87 in RNA-seq subset (reported in study)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq) and recurrence across samples</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known activating residues in RAS family; no new functional assays presented here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Reported as driver mutations; low frequency</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Pathway-relevant (RAS/MAPK) but no targeted therapy data in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset) where reported</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e27.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF V600E (v-raf murine sarcoma viral oncogene homolog B1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activating BRAF V600E substitution observed in one lung adenocarcinoma sample in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAS-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Well-characterized activating mutation in prior literature; no new functional data in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Rare in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>BRAF inhibitors are clinically relevant in other contexts (not tested here)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e27.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PI3K catalytic subunit with activating hotspot (H1047R) and another mutation (E555K) observed in two cases, representing PI3K pathway alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA H1047R; E555K</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA / PI3K-AKT pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>2/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq); recurrence</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>H1047R is a known activating mutation from prior studies; no new functional assays here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed as co-occurrence in one EGFR+PIK3CA double-mutant case in the larger cohort (exception to mutual exclusivity)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>PI3K pathway targetability suggested but not tested</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e27.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CTNNB1 D32G</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Catenin beta 1 (beta-catenin) D32G</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An activating substitution in CTNNB1 (D32G) observed in one sample, a mutation known to be oncogenic in other cancers and suggested here to be able to induce lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CTNNB1 D32G</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CTNNB1 / WNT signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq) and literature precedent</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Previously reported activating mutation in other cancers; no new functional tests here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Single-sample observation; suggested as capable of inducing lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>None reported in this study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e27.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET (point)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET proto-oncogene (M1124D)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A MET missense mutation (M1124D) observed in one sample; MET is a receptor tyrosine kinase implicated in lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET M1124D (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq) and literature precedent</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Previously reported activating mutation in other cancers; no functional assays in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Single-sample occurrence</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>MET is targetable in other contexts; not tested here</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e27.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET exon 14 skipping</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET exon 14 skipping (alternative splicing)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent exon 14 skipping events in MET detected in three tumors; exon 14 skipping removes regulatory sequences and is likely activating for MET.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET exon 14 skipping (E14 skipped)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>alternative splicing / exon skipping (transcriptional variant activating RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3/87 in RNA-seq subset; 3/200 (1.5%) in total cohort reported</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>All 3 tumors did not carry canonical point driver mutations or canonical transforming fusion genes (observed in driver-negative subset; P=0.057 for exclusivity)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome profiling (exon read-depth, exon-skipping reads) and recurrence across samples</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Previously reported in literature as oncogenic (cited Kong-Beltran et al. 2006); here inferred as likely driver due to absence of canonical drivers, but no new functional assays performed</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed in tumors lacking canonical point drivers / canonical fusion drivers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Implicates MET-directed therapies as potential interventions; paper suggests likely driver but no clinical response data</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset); 200 overall cohort for prevalence</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq exon coverage and exon-skipping read analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e27.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A canonical, oncogenic fusion between EML4 and ALK producing a chimeric tyrosine kinase observed in the cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EML4-ALK fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 detected by RNA-seq in this subset; 7 additional EML4-ALK fusions were found by FISH in total 200 cohort (total EML4-ALK count in summary not individually enumerated beyond combined fusion counts)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>ALk fusions were mutually exclusive with canonical point driver mutations; samples with ALK fusions did not carry canonical point drivers (co-occurrence low/none)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome profiling (fusion detection) and orthogonal validation (PCR/Sanger, FISH in some samples)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Established oncogenic fusion with known sensitivity to ALK inhibitors (discussed in paper, e.g., crizotinib); no new in vitro assays here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutually exclusive with canonical point drivers in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Known target (crizotinib) â€” discussed in paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset) and 200 total cohort (FISH screening)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq GFP fusion detection pipeline; PCR and Sanger validation; FISH for some samples</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e27.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-RET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B-RET fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent RET fusion with KIF5B producing an oncogenic RTK fusion found in multiple samples (four cases in RNA-seq subset).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KIF5B-RET fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>4/87 in RNA-seq subset; RET fusions reported among total cohort</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Specimens carrying these RTK fusions did not harbor canonical point driver mutations (fusion-positive cancers were enriched in driver-negative tumors; P-values reported)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome profiling (fusion detection), validation by PCR/Sanger (where primer available)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>RET kinase domain present in fusion and literature supports transforming activity; no new functional assays here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutually exclusive with canonical point drivers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>RET fusions are potentially druggable (RET inhibitors), suggested as targets</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset); 200 total for cohort-level fusion frequency</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq fusion calling (GFP), PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e27.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 fusions (CD74/SLC34A2/CCDC6)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene fusions (CD74-ROS1, SLC34A2-ROS1, CCDC6-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Interchromosomal fusions involving ROS1 creating chimeric tyrosine kinases; two canonical fusion partners and one novel partner (CCDC6) were detected.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CD74-ROS1; SLC34A2-ROS1; CCDC6-ROS1 (novel)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>CD74-ROS1: 1/87; SLC34A2-ROS1: 1/87; CCDC6-ROS1 (novel): 1/87 (each observed as singletons in RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>CCDC6-ROS1 and other ROS1 fusions were found in tumors without canonical point drivers (no canonical point driver mutations present in these fusion-positive tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection and PCR/Sanger validation; mutual exclusivity analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>ROS1 kinase domain present in fusions; known transforming potential from prior literature for canonical partners; novel CCDC6-ROS1 carries kinase domain and dimerization unit suggesting activation (inferred)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Fusion-positive specimens tended to lack canonical point drivers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ROS1 fusions are clinically actionable with ROS1 inhibitors (implied), novel partner may also be targetable</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq fusion calling, PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e27.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CCDC6-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CCDC6--ROS1 fusion (novel)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel ROS1 fusion partner (CCDC6) detected in one tumor; fusion retains ROS1 kinase domain and a dimerization unit in partner, supporting oncogenicity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CCDC6--ROS1 gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase, novel)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset (singleton); rare</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Observed in tumor lacking canonical point drivers (fusion-positive and driver-negative association reported)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection and PCR/Sanger validation; domain architecture inference (kinase + dimerization unit)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Inferred activating potential due to kinase domain and dimerization motifs; no direct functional assays performed in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in a tumor without canonical drivers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Likely targetable with ROS1 inhibitors; authors suggest potential druggability</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq (GFP), PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e27.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FGFR2-CIT</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>FGFR2--CIT fusion (novel)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel fusion joining FGFR2 (a receptor tyrosine kinase) to CIT detected as an in-frame fusion retaining kinase domain, suggesting oncogenic activation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FGFR2--CIT gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase, novel)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>FGFR2 / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset (singleton)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Observed in a tumor lacking canonical point drivers (no canonical drivers present in that sample)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection and PCR/Sanger validation; domain retention analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Inferred activating potential because FGFR2 kinase domain retained; no direct functional experiments reported</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in driver-negative tumor</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>FGFR2 fusions are potentially targetable with FGFR inhibitors; suggested as candidate target</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq (GFP), PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e27.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AXL-MBIP</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AXL--MBIP fusion (novel)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Novel fusion joining AXL (a receptor tyrosine kinase) to MBIP, retaining kinase domain and dimerization motifs implying activating function.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>AXL--MBIP gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chimeric tyrosine kinase, novel)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>AXL / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset (singleton)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Detected in a tumor lacking canonical point driver mutations</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection, PCR/Sanger validation, domain architecture inference</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Inferred activating potential (kinase + dimerization motifs); no in vitro/in vivo functional tests in this study</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in driver-negative tumor</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>AXL-targeted strategies could be relevant; paper notes potential druggability</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq fusion calling, PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e27.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SCAF11-PDGFRA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SCAF11--PDGFRA fusion (novel; promoter swap)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel fusion placing PDGFRA under control of the SCAF11 promoter (promoter swapping), likely leading to PDGFRA overexpression and oncogenic signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SCAF11--PDGFRA fusion (promoter swap)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (promoter swapping leading to overexpression; tyrosine kinase involvement)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PDGFRA / RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1/87 in RNA-seq subset (singleton)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Detected in tumor lacking canonical drivers</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection and PCR/Sanger validation; mechanism inferred (promoter swapping)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Inferred driver by promoter swap causing overexpression of PDGFRA; no direct functional validation in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in driver-negative tumor</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>PDGFRA inhibitors may be relevant; paper suggests potential druggability</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq fusion calling (GFP), PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e27.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other kinase fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Other kinase-containing fusions (MAP4K3-PRKCE; BCAS3-MAP3K3; ERBB2IP-MAST4, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Additional in-frame fusions involving serine/threonine kinases and signaling genes were identified as candidate functional events in some tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MAP4K3--PRKCE; BCAS3--MAP3K3; ERBB2IP--MAST4; APLP2--TNFSF11; KRAS--CDH13; ZFYVE9--CGA; TPD52L1--TRMT11</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusions (serine/threonine kinases, signaling fusions)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Various kinases / signaling pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Each observed as singletons in the RNA-seq subset (1/87 each)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Noted as candidate functional events; specific driver-negative frequencies not explicitly quantified</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>transcriptome fusion detection and PCR/Sanger validation (most validated where primers available)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Potential functional importance inferred from gene function (kinases, signaling), but no direct functional assays reported</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Noted as possible contributors to tumor biology in individual samples</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potentially targetable depending on kinase â€” requires further functional assessment</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq (GFP pipeline) and PCR/Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e27.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor protein p53</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor suppressor gene frequently mutated across the cohort; TP53 mutation co-occurrence with oncogenic drivers was associated with higher rates of lymph node metastasis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TP53 somatic mutations (various)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (loss-of-function / disruptive)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TP53 / tumor suppressor pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Most frequently mutated gene in the study cohort among genes reported (exact count not stated in main text but noted as highest frequency)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq and exome sequencing), statistical association with metastasis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Well-established tumor suppressor in prior literature; study reports association with increased lymph node metastasis when combined with driver mutations (multivariate logistic regression P=0.017)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Co-occurrence with driver mutations associated with higher lymph node metastasis rates</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Prognostic association suggested; no direct therapeutic strategy addressed</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>200 total; 87 RNA-seq subset</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and whole-exome sequencing (for some samples)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e27.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CDKN2A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cyclin dependent kinase inhibitor 2A</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor suppressor gene frequently altered in the cohort and highlighted as noteworthy for its likely role in tumorigenesis or maintenance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Mutations/deletions/alterations (specific variants not detailed in main text)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function / mutation / copy-number alteration (implied)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Cell cycle regulation / tumor suppressor</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Reported among frequently altered genes (exact count not provided in main text; â‰¥3 mutations threshold for listing)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome), recurrence across samples</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known tumor suppressor; no new functional validation in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Flagged as frequently altered; details in supplemental data</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>None specified</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 RNA-seq subset (primary reporting)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.18">
                <h3 class="extraction-instance">Extracted Data Instance 18 (e27.18)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NOTCH2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NOTCH2 receptor</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>NOTCH2 identified among frequently altered genes in the cohort and considered potentially related to tumorigenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Somatic mutations / alterations (specific variants not detailed in main text)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / potential loss/gain of function</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NOTCH signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Listed among frequently altered genes (exact count in supplemental data)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome) and recurrence</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not provided in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.19">
                <h3 class="extraction-instance">Extracted Data Instance 19 (e27.19)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SMARCA4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 (BRG1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chromatin remodeling gene frequently altered in the cohort and implicated as a candidate cancer gene in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Somatic mutations (loss-of-function candidates)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation / truncation (implied)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Chromatin remodeling (SWI/SNF complex)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Listed among frequently altered genes (exact count in supplemental tables)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not provided in this study; gene previously implicated in cancer</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not specified in main text</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.20">
                <h3 class="extraction-instance">Extracted Data Instance 20 (e27.20)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LMTK2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Lemur tyrosine kinase 2</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Gene newly implicated by recurrent alteration in a subset of tumors and highlighted as a candidate novel driver.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Somatic mutations / recurrent alterations (specific variants not detailed in main text)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>LMTK2 (kinase-related signaling)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Listed among frequently altered genes in figure/table (exact counts in supplemental data)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome), recurrence</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not provided here; suggested as candidate based on recurrence/overexpression</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.21">
                <h3 class="extraction-instance">Extracted Data Instance 21 (e27.21)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ARID1A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AT-rich interaction domain 1A (SWI-like)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chromatin remodeling tumor-suppressor gene frequently altered in some cancers and identified among recurrently altered genes in this lung cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Somatic mutations (candidate loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Chromatin remodeling / SWI/SNF complex</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Listed among frequently altered genes (count in supplemental data)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not shown in this paper; recurrence suggests involvement</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.22">
                <h3 class="extraction-instance">Extracted Data Instance 22 (e27.22)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MTOR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mechanistic target of rapamycin</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MTOR listed among genes altered in the cohort and suggested to be of interest due to its role in growth signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Somatic alterations / mutations (specific variants not detailed in main text)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / pathway alteration (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MTOR / PI3K-AKT-mTOR signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Listed among frequently altered genes (exact counts in supplemental data)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (RNA-seq/exome)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not provided here</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not specified</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>mTOR pathway is targetable in general, but no specific clinical data here</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>87 (RNA-seq subset)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq and exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e27.23">
                <h3 class="extraction-instance">Extracted Data Instance 23 (e27.23)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>JRBs / CNAs</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Jointly regulated blocks and copy number alterations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Genomic regions where groups of genes are coordinately over- or under-expressed (JRBs) that correlate strongly (~70%) with copy number alterations measured by CGH arrays.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The transcriptional landscape and mutational profile of lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Large-scale co-localized expression changes explained by copy number alterations (gains/losses) and possibly methylation</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy number alteration / epigenetic domain changes (large blocks)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Genome-wide co-regulated blocks (multiple genes/chromosomal arms)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>JRBs observed variably across samples (number per sample highly variable); ~70% of JRBs explained by CNAs in subset with CGH</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>integrated transcriptome profiling and CGH array comparative analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Correlation between averaged JRB Z-scores and CGH log2 ratios (r^2 reported); supports structural variation driving expression changes</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>JRB patterns nonrandom (e.g., gains on chr7p frequently increased, losses on chr3p decreased) and correspond to known cancer CNAs</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potentially explains large-scale expression perturbations; no direct therapeutic link established in study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>JRBs derived from 87 RNA-seq samples; CGH validation on n=9</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq expression ratios and Agilent 180K CGH arrays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'The transcriptional landscape and mutational profile of lung adenocarcinoma', 'publication_date_yy_mm': '2012-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing <em>(Rating: 2)</em></li>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>Somatic mutations lead to an oncogenic deletion of MET in lung cancer <em>(Rating: 1)</em></li>
                <li>RET, ROS1 and ALK fusions in lung cancer <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>